Background Despite the molecular heterogeneity of standard-risk acute myeloid leukemia
(AML), treatment decisions are based on a limited number of molecular genetic markers and …

NPM 1-mutated acute myeloid leukemia (AML) shows unique features. However, the
characteristics of “therapy-related” NPM1-mutated AML (t-NPM1 AML) are poorly …

Abstract Mutations in Nucleophosmin 1 (NPM1) are associated with a favorable prognosis in
newly diagnosed acute myeloid leukemia (AML), however, their prognostic impact in …

Abstract Nucleophosmin (NPM1)–mutated acute myeloid leukemia (AML), which is
recognized as a provisional entity in the World Health Organization 2008 classification of …

Mutations of Nucleophosmin (NPM1) are the most common genetic abnormalities in adult
acute myeloid leukaemia (AML), accounting for about 30% of cases. NPM1-mutated AML …

Acute myeloid leukemia (AML) with mutated NPM1 is a newly recognized separate entity in
the revised 2016 World Health Organization classification and is associated with a favorable …

Mutations of the NPM1 gene (NPM1 mut) are among the most common genetic alterations in
acute myeloid leukemia and are suitable for minimal residual disease detection. We …

Assessment of measurable residual disease (MRD) by quantitative reverse transcription
polymerase chain reaction is strongly prognostic in patients with NPM1-mutated acute …

Mutations in the nucleophosmin 1 (NPM1) gene are considered founder mutations in the
pathogenesis of acute myeloid leukemia (AML). To characterize the genetic composition of …

In AML patients, recurrent mutations were shown to persist in remission, however, only some
have a prognostic value and persistent mutations might therefore reflect a re-established …